Compare Becton Dickinson and Co (BDX) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Ferrari NV — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Ferrari NV trades at $371.07 (market cap $65.00B). The key difference: Ferrari NV is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | RACE | |
|---|---|---|
Market Cap | $41.51B | $65.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $517.65 |
52-Week Low | $135.49 | $314.63 |
Enterprise Value | $57.97B | $66.21B |
Dividend Yield | 2.79% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Ferrari (RACE) trades at $372.98, down 0.97% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong profitability with a net income margin of 22.19% and robust revenue growth from $5.1B in 2022 to $7.1B in 2025. Recent news highlights the company's ongoing share buyback program and strategic moves in the EV space, though the Luce model has faced some market skepticism.
The outlook remains positive with a consensus price target of $467.50, implying significant upside. Key opportunities include pricing power and margin strength, while risks involve execution on EV strategy and high valuation multiples. Earnings consistently beat expectations, supporting the bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
